Antihistamine activity and central effects of WAL 801 CL in man
- 29 Downloads
The tolerability and antihistaminic activity of WAL801 CL, a new, peripherally acting H1-receptor antagonist, have been evaluated in a double-blind, placebo-controlled, within-subject cross-over study.
WAL801 CL 8 mg b.d. was given to 10 healthy volunteers for 15 days.
It resulted in a distinct reduction in histamine wheal size and a decreased bronchoconstrictor response to histamine inhalation.
No cardiovascular side effects were observed. Transient and slight fatigue was observed in 3 subjects. Psychological tests, such as simple visual reaction time, critical flicker fusion frequency and mood self rating scale, showed that WAL801 CL had no sedative side effects and that it did not alter psychomotor performance.
Key wordsWAL801 CL antihistamine skin wheals bronchospasm central effects adverse effects
Unable to display preview. Download preview PDF.
- 1.Adamus WS, Oldigs-Kerber J, Lohmann HF (1987) Pharmacodynamics of the new H1-antagonist-3-amino-9,13b-dihydro1H-dibenz[c, f]imidazo[1,5-a]azepine hydrochloride. Arzneimittelforsch/Drug Res 37: 568–572Google Scholar
- 2.Janke W, Debus G (1978) Die Eigenschaftswörterliste EWL. Hogrefe, Göttingen, FRGGoogle Scholar
- 3.Reinberg A, Levi F, Guillet P, Burke JT, Nicolai A (1978) Chrononpharmacological study of antihistamines in man with special references to terfenadine. Eur J Clin Pharmacol 14: 245–252Google Scholar
- 4.Seppälä T, Savolainen K (1982) Effect of astemizole on human psychomotor performance. Curr Ther Res 31: 638–644Google Scholar
- 5.Nicholson AN, Stone BM (1982) Performance studies with the H1-histamine receptor antagonists, astemizole and terfenadine. Br J Clin Pharmacol 13: 199–202Google Scholar
- 6.Nicholson AN (1982) Antihistaminic activity and central effects of terfenadine. Drug Res 32: 1191–1193Google Scholar